Remove 2023 Remove Conditions Remove DEA
article thumbnail

MDMA Failed to Receive FDA Approval: What Happens Next?

Veriheal

PTSD in the US population is estimated to produce an economic burden of about $232 billion annually , costing more economic excess per person affected than coronary heart disease (CHD), anxiety, or major depressive disorder (MDD), both of which are considered to be relatively costly health conditions.

article thumbnail

The Week in Weed: December 15, 2023

The Blunt Truth

The DEA sends a letter to Georgia pharmacies. Apparently, HHS was interested in the experiences of medical marijuana users, and how cannabis helped them with their conditions. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it. makes an appearance in Congress.

DEA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HSS Releases Full Recommendation Report for Rescheduling Cannabis: What Will This Mean for Med & Rec Markets?

Veriheal

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The HSS found strong scientific support regarding cannabis’ medically beneficial effects for conditions like anorexia , nausea, and chronic pain.

article thumbnail

Emerge Law Group (OR): PSILOCYBIN THERAPY FOR PATIENTS WITH ADVANCED ILLNESS IN OREGON

Cannabis Law Report

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52
article thumbnail

Psychedelic Users Tend to Be ‘One With Nature’ and Are More Passionate About Climate Change, Study Finds

Veriheal

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

article thumbnail

PHILLIPS LYTLE LLP LAUNCHES PSYCHEDELICS & MENTAL HEALTH THERAPIES PRACTICE

Cannabis Law Report

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Tweet this. However, change appears imminent.

Therapy 52
article thumbnail

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories.